Sino Biopharmaceutical enrolls first patient in phase 1 TRD208 pain relief trial

Sino Biopharmaceutical Limited has announced the successful enrollment of the first patient in the Phase 1 clinical trial in China for TRD208, a National Class 1 innovative drug. TRD208 is described as a First-in-Class, non-opioid, multi-target, multi-modal analgesic, designed to address acute pain management. The company anticipates TRD208 will offer rapid onset, potent analgesic effects, and prolonged action, potentially replacing current mainstream combination therapies by achieving multi-modal analgesic effects as a single agent.

TRD208's mechanism blocks multiple pain transmission pathways, including NaV1.7 and NaV1.8, and exhibits peripheral anti-inflammatory and analgesic effects similar to NSAIDs, while also suppressing central sensitization. This development reinforces Sino Biopharmaceutical's focus on innovative non-opioid targeted drugs within the surgery/analgesia therapeutic area.

Concurrently, the company's monthly return for November 2025 indicates that its issued ordinary share capital remained stable. As of November 30, 2025, the number of issued shares was 18,760,717,230, with no movements in issued shares or treasury shares reported for the month. The total authorised/registered share capital also remained unchanged at 30,000,000,000 HKD.